SAN ANTONIO, 03/24/2016 /SubmitPressRelease123/

When North Park Lexus at Dominion opened its doors in 2014, it did so with the intention of providing drivers more than just stunning luxury cars, but an exceptional shopping experience, too. Early efforts to provide San Antonio drivers with a luxurious dealership experience have been successful, as North Park Lexus at Dominion has earned an Elite of Lexus award for its inaugural year, joining a select group of the county’s most remarkable car dealerships.

In order to be honored with the prestigious Elite of Lexus award, which only seven other dealerships in Texas won for 2015, North Park Lexus at Dominion had to prove itself worthy of such a title through exceptional sales and service satisfaction. Winners are determined based on customer feedback from surveys rating owner satisfaction and the sales and services processes. Those dealers that consistently rank as exceptional and that exceed Lexus’ certification standards are recognized for their hard work. The award is reserved for dealers that truly excel in everything they do, from sales to service to the overall ownership experience. It’s a highly coveted honor amongst dealers, as Elite of Lexus status cements a dealership’s place as one of the foremost Lexus dealerships in the U.S.

“It’s truly an honor to be recognized with such a prestigious accolade, and during our first year in business nonetheless,” said Todd Vagi, General Sales Manager of North Park Lexus at Dominion. “When a customer visits our San Antonio Lexus dealership, our goal is always to exceed their expectations from test-drive through delivery. We’d like to thank the amazing Lexus owners and the surrounding San Antonio community for helping us achieve this coveted distinction.”

Those who visit North Park Lexus at Dominion are treated to a one-of-a-kind, resort-style dealership experience. The custom-built 72,000-square-foot luxury dealership is fully equipped with a litany of perks for shoppers, including eight fireplaces to relax by, a private massage room, a nail salon, quiet areas for reading and meditation, a beverage and snack bar and much more. With a no-haggle price policy, a vast selection of new and pre-owned Lexus vehicles and a desire to cultivate a unique car-buying and -servicing environment, the South Texas Lexus dealership differentiates itself from others in its area.

About North Park Lexus at Dominion:

Since opening its doors in 2014, the North Park Lexus at Dominion’s goal has been to provide its customers a home away from home. As a member of the prestigious Kahlig Auto Group, North Park Lexus at Dominion brings Texas drivers more than 15 years of customer service experience in a brand-new environment. Its resort-style showroom is one-of-a-kind, as it provides customers a relaxing dealership environment and a host of exclusive perks. The South Texas Lexus dealership combines a vast selection of the finest new and pre-owned Lexus models with a top-notch service center to ensure excellence throughout the ownership experience. Find North Park Lexus at Dominion online at www.northparklexusatdominion.com or on Facebook at www.facebook.com/NorthParkLexusatDominion. You can also call their sales team at 210-816-6000 or visit the dealership at 21531 Interstate 10 Frontage Rd. in San Antonio.

Like Us on Facebook

Read the full story at http://newsreleases.submitpressrelease123.com/2016/03/29/north-park-lexus-at-dominion-wins-elite-of-lexus-award/

ReleaseID: 19113

March 29, 2016 – – BloodThinnerHelp.com reports on the recently granted Precription Drug User Fee Act (PDUFA) action date for Portola Pharmaceuticals’ developing anticoagulant antidote, Andexanet Alfa. According to reports from seekingalpha.com, Portola Pharmaceuticals was recently granted a PDUFA from the FDA for the developing antidote for August 17, 2016. While the antidote has yet to be approved, the new antidote could have the potential to change the leaders in the anticoagulant market by changing the types of anticoagulants preferred by doctors, according to the report. The new drug is expected to reverse the effects of anticoagulants including blood-thinning drugs like Xarelto.

Though the new drug may counter the adverse side effects many have associated with Xarelto, thousands of patients have already claimed to have been negatively affected by the drug.

Xarelto, manufactured by Bayer AG and Johnson & Johnson, was first introduced in the U.S. when it was approved by the FDA in 2011 for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, atrial fibrillation, and general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. The first case alleging that the drug was the cause of death because of uncontrollable bleeding was filed in 2014. Other injuries that plaintiffs have associated with Xarelto have included stroke, heart attack, internal bleeding, gastrointestinal bleeding, epidural hematoma, rectal bleeding and pulmonary embolisms.

For more effective handling of the nearly 3,000 cases that have been filed federally, a multidistrict litigation panel was formed in New Orleans, Louisiana. Presiding over those cases will be Judge Eldon E. Fallon, who has set dates for the bellwether trials in for those cases to begin in February 2017. About 40 cases have been chosen.

While those cases approach a trial date, Attorney Joseph Osborne is working to ensure that those individuals who believe they have been negatively affected by the drug have the opportunity to fully explore their legal rights. Qualifying individuals may be entitled to legal action and substantial financial compensation. Osborne is currently offering complimentary legal consultations for affected parties.

To learn more about Xarelto, or to ask questions, contact Joseph Osborne, Esq. at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008939

Philadelphia area startup releases WheyClean® Bottle Cleaner, the solution for that “dirty shaker bottle” smell!

PHILADELPHIA, PA – 29 Mar, 2016 – Whether it’s from protein shakes, smoothies, or other nutrition shakes, we all know what gets left behind… the smell! WheyClean® Bottle Cleaner is a travel friendly single-use cleaning powder for shaker bottles and similar containers. WheyClean® goes to work quickly and powers through stains and odors in seconds, wherever you happen to be. Mineral-based and chlorine free, WheyClean® is the best way to safely and easily clean your bottles anywhere you need to do it. 

WheyClean® Demo Day!
As a Philadelphia area startup, WheyClean® will be demoing their product at the GNC in Newtown PA, on April 13th, 2016. 

About WheyClean®

WheyClean® Bottle Cleaner was founded in 2015 by Michael Wasyl and Derick Hughes, room mates at The College of New Jersey who were sick and tired of ruined fitness shaker bottles due to lingering odors and stains. Whether in the locker room, between classes, or traveling, there was just no easy way to effectively clean their shakers without using overly scented hand or dish soaps that only masked the odors. As a result, WheyClean® was born to offer athletes and fitness enthusiasts the perfect way to keep their bottles clean and ready to go for the day. 

WheyClean® is the only bottle cleaner formulated to tackle the nasty odors and stains left behind protein powders, smoothies, or other nutrition shakes. Packaged for convenience, WheyClean® is what your bottle is missing! If you have a shaker bottle, you have to have WheyClean®.

WheyClean® Bottle Cleaner is now available on Amazon at:
http://www.amazon.com/s/ref=nb_sb_noss_2/183-6487423-9501857?url=search-alias%3Daps&field-keywords=wheyclean

Visit: http://www.wheycleanusa.com for more information. 

Photo Credit: Anthony Stull
http://www.anthonystullphoto.com/

Company Contact:
WheyClean LLC
PO Box 736
Washington Crossing, PA, 18977
contact@wheycleanusa.com

Full News Story: http://pressreleasejet.com/news/philadelphia-startup-solves-the-problem-of-the-smelly-fitness-shaker-bottle.html

Media Contact
Company Name: Wheyclean LLC
Contact Person: Michael Wasyl
Email: michaelwasyl@wheycleanusa.com
Country: United States
Website: www.wheycleanusa.com

ReleaseID: 541845

Source: GetNews

March 29, 2016 – – BloodThinnerHelp.com reports on an article recently published on Health News Review by a guest blogger psychiatrist from the Washington, DC area. The article discusses what many different media outlets have been reporting recently: controversies surrounding critical clinical trials conducted on blood-thinning drug Xarelto, as well as data which may have been left out of a report to the New England Journal of Medicine.

The subject of these controversies is anticoagulant drug Xarelto, a new-generation blood thinner which was approved by the U.S. Food and Drug administration and released to market in 2011. This approval, however, as is now being discussed, may have been premature due to potentially incomplete clinical trial reports and a potentially faulty testing device during those clinical trials. The trials were meant to compare Xarelto to warfarin, a traditional blood thinner. When the BMJ reported that a malfunctioning blood test device was used during the trial, and that patients in the coumadin group may have been given higher doses of coumadin than what was considered optimal, patients from across the nation began to increasingly question Xarelto.

According to the Health News Review article author, “This isn’t the first time the NEJM has been embroiled in controversy over missing data. The Times referenced a past situation where NEJM editors knew of missing heart attack data from a clinical trial and allowed the study to be published anyway. The drug that was studied, the painkiller Vioxx (rofecoxib), was eventually withdrawn from the market, but not before leading to an estimated 55,000 deaths, as well as thousands of heart attacks and strokes.”

The author continues to discuss new medical reporting ethics which have been brought into question surrounding the drug. The author discusses transparency within data sharing and the importance of this honesty, stating, “As I pointed out in January, the NEJM editors have recently made a case against transparency and data sharing, in opposition to the push for universal acceptance of these principles by many in the research community. After publicly raising concerns that data-sharing would benefit so-called ‘research parasites’ who might have the temerity to use the data ‘to try to disprove what the original investigators had posited,’ Dr. Drazen quickly clarified that his stance against data-sharing didn’t apply to clinical trials such as the Xarelto study.”

These controversies only add to many allegations already surrounding the new-generation blood-thinning drug among patients from across the nation who have stepped forward to file lawsuits alleging that the drug can cause dangerous and even fatal bleeding side effects. Lawsuits now number over 3,400 across the United States, and have been consolidated to form two major groups. Federally-filed cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 in Eastern Louisiana. They currently number over 2,800 complaints. In addition, more than 600 complaints have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort program.

As many plaintiffs await results of investigations surrounding these new controversies, and await trial dates as well, Attorney Joseph Osborne is working to ensure that anyone else who may have taken Xarelto and suffered from adverse health events that they attribute to their use of the drug will be afforded the important opportunity to fully explore their legal rights at this time. Affected patients may be eligible for significant compensation gained through legal action. To help those wishing to explore this avenue, Attorney Osborne is currently offering free legal consultations for affected parties.

To request additional information concerning Xarelto lawsuits, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008950

Ticket Down has rolled back ticket prices across the board for USA vs. Guatemala at Mapfre Stadium in Columbus. This well known site is offering their customer appreciation promo code SOCCER for added savings.

Ticket Down is a reputable source of authentic tickets for the USA Mens National Soccer Team vs. Guatemala at Mapfre Stadium in Columbus tonight at 7:00 p.m. This 2018 World Cup Qualifier is a must win for the United States Men’s National Team after suffering their first loss to Guatemala since 1988 this past Friday. Currently the United States is 2 points behind Guatemala in their four team group which also includes Trinidad and Tobago and St. Vincent and the Grenadines.

Mapfre Stadium was formerly known as the Columbus Crew Stadium and it is the home of the Columbus Crew from Major League Soccer (MLS). In addition to hosting soccer events, this venue also hosts lacrosse, rugby and football games. The stadium has a permanent stage on the north end and it annually hosts the Rock on the Range Festival.  Rascal Flatts, a popular band that hails from Columbus has also performed here in front of sellout crowds.

About TicketDown.com:

Ticket Down delivers tickets to sold out concerts and events worldwide when no one else can, and they do so at discounted prices. This popular ticket site also has discounted tickets for the USA vs. Guatemala World Cup Qualifier in Columbus tonight. We also have cheap tickets for all upcoming Copa America Centenario events along with tickets for the International Champions Cup featuring premier worldwide teams competing in North America beginning on July 24th. Soccer fans are encouraged to add promo code SOCCER for added savings.

Note: Ticket Down is not associated with any soccer teams mentioned in this release. The names that are used in this release are purely for descriptive purposes. We are not affiliated with nor do we endorse any sports teams or venues in this release. TicketDown.com and JP Media, LLC are not responsible for any errors or omissions in this release.

Check out our discount codes online for all upcoming events. Ticket Down has low overheads which allow this well-known ticket site to keep prices competitive.

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/03/1426775372.jpeg

“Ticket Down is a reputable source of authentic tickets for USA vs. Guatemala at Mapfre Stadium in Columbus on 3/29/16. Add promo code SOCCER at the checkout.”

Media Contact
Company Name: JP Media
Contact Person: Ticket Down
Email: contact@ticketdown.com
Phone: 1-877-870-3653
Country: United States
Website: www.ticketdown.com

Source: ABNewswire

ReleaseID: 57551

The Global 3D Printing Materials Market is estimated to grow at a high CAGR of 29.6% during the forecast period due to growing demand for 3D printed parts and accessories from major industries like Consumer, Aerospace and Defense, Automobiles and Others.

The Report “3D Printing Materials Market by Type Plastics (PLA, ABS, PVA), Metals (Titanium, Steel, Silver), Ceramics]; By Form (Filament, Powder, Liquid); Application (Aerospace, Automotive, Industrial, Healthcare) – (2013 – 2020)”, published by IndustryARC.

Browse through the Report Description, in-depth Table of Contents and Customization Options:
http://industryarc.com/Report/186/3d-printing-materials-market.html

3D Printing has begun to flourish in various application areas including aerospace, automobile, consumer, and medical. The materials used for these purposes vary accordingly. As per IndustryARC analysis the 3DP materials market has revenue of $351.4 Million as of 2013 where consumer 3D printing is the major market share of 46% in 2013. Consumer 3D printers majorly uses plastic and the consumption of plastics is expected to increase dramatically in the future as the number of consumer printers shipped are showing the trend of doubling each year till 2020 which will also affect the consumption of plastics in a positive way. Metals have unique properties which increases their demand in various applications. At present, 3D printing of metals is widely used in applications such as aerospace and defense, automobiles and so on and it is slowly penetrating into various other applications.

Aerospace industry widely uses Titanium which is very much lighter compared to other metals and has great strength. So using these parts will increase the efficiency of the spacecraft. But its use is limited because of high cost, for instance: one kilo of 3D printing titanium will cost around $200-$300 as compared with other metals such as aluminum, steel and so on. But its consumption is expected to increase not only in aerospace but also in other applications as the cost of 3D printed titanium powder is expected to fall below $100 (a kilo) as the U.K. based Metalysis have developed a cost efficient way to produce low cost titanium powder for 3D printing.

Request for a Sample Brochure @ http://www.industryarc.com/pdfdownload.php?id=186

Currently, plastics are the most widely used materials in additive manufacturing due to the growth in consumer 3D printing industry and some of the important plastics include ABS, PLA, PVA and PET. ABS and PLA together accounted for 70.0% of the global 3D printing plastics market. With the invention of home 3D printers that uses plastic filaments to 3D print of any object, the demand for these materials has grown tremendously and this trend is expected to continue in the next five years.

Metals are the strongest materials available in the market, but are extremely expensive. Metals such as: steel, titanium, aluminum, copper, silver, gold, nickel, cobalt and others. Metal 3D printing is a costly method and hence, metal materials are limited to high-end applications like aerospace and automobiles. A range of other manufacturing materials that can be used for 3D printing include: nylon, glass-filled polyamide, epoxy resins, wax and paper. This report published by IndustryARC has defined market for each of these materials with respective applications for each region and major countries. Major manufacturers of 3D printing materials like 3D Systems, Stratasys, Materialise N.V., and EOS GmbH and so on are analyzed and profiled in this report. Stratasys Ltd. and 3D Systems are the two key market players in the 3DP materials industry. While Stratasys occupies 34% of the market, 3D Systems has a market share of 32% of the global additive manufacturing materials market.

Huge investments are pouring into this industry through various sources for various research purposes, which would result decrease in prices of available products and also develop new 3DP materials in the future which would increase the demand of these products. Even various government bodies like National Aeronautics and Space Administration (NASA) and others have also started to explore the 3D printing market. Consumer 3D printing industry is growing at a rapid rate of approximately 40% compared to any other industry in 3D printing and the consumer 3D printers were expected to reach 1 million shipments in 2013 with most of its demand from North America.

Inquiry with our Analyst before Buying @ http://www.industryarc.com/inquiry-before-buying.php?id=186

Browse Related Reports:

• Consumer 3D Printing Market Analysis: By Materials Used ( Plastics, Metals, Ceramics, Form);By End Users (Households, Educational Institutions, Food Industry, Small & Medium Businesses)- With Forecast (2015 – 2020):
  http://industryarc.com/Report/79/global-consumer-3d-printing-market-analysis.html

• 3D Printing in Healthcare Market: Role and Opportunities: By Technology (LBM, EBM, Stereolithography and others); By Material (Metal, Cells and others); By Application (Implants, Tissue Engineering and others) & By Geography – Forecast (2015 – 2020):
  http://industryarc.com/Report/1268/3D-printing-in-healthcare-market-analysis.html

About IndustryARC:

IndustryARC is a Research and consulting firm that publishes more than 500 Reports Annually in various industries, such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences & Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications of the Market. Our Custom Research Services are designed to provide insights on the constant flux in the global demand-supply gap of markets. Our strong analyst team enables us to meet the client research needs at a very quick speed with a variety of options for your business.

We look forward to support the client to be able to better address customer needs; stay ahead in the market; become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/03/1459144208.jpeg

“Growing Popularity of 3D Printing Technology is Pushing the 3D Printing Materials Market.”

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Sanjay Matthews
Email: sales@industryarc.com
Phone: 1-614-588-8538 (Ext: 101)
Country: United States
Website: http://www.industryarc.com

Source: ABNewswire

ReleaseID: 57549

David Gilmour concert tickets for his 2016 Chicago, IL tour dates are on sale now for discount prices with promo code. Trusted secondary ticket market provider CapitalCityTickets.com is providing David Gilmour fans with a promo code CITY5 to save an additional 5% on all orders.

CapitalCityTickets.com carries a vast selection of David Gilmour concert tickets at affordable prices. David Gilmour will perform at the United Center in Chicago, IL on April 4^th and 8^th.

David Gilmour is an English musician, singer, songwriter and multi-instrumentalist. In a career spanning more than 50 years, he is best known for his work as the guitarist and co-lead vocalist of the progressive rock band Pink Floyd.

CLICK HERE to browse all levels of seating for David Gilmour concerts at CapitalCityTickets.com.

CapitalCityTickets.com stocks all levels of seating and price ranges to all David Gilmour concerts! CapitalCityTickets.com also offers a safe online buying experience for David Gilmour tickets.

Save time and money with CapitalCityTickets.com, all of the tickets are backed with a 200% money back guarantee.

Follow on Social Media for Special Deals and Discounts

Facebook: http://www.facebook.com/CapitalTickets

CapitalCityTickets.com
Live Customer Support
Order By Phone Toll Free 7 Days a Week
(855) 514-5624

Browse the inventory of tickets for David Gilmour at CapitalCityTickets.com today and save! http://www.capitalcitytickets.com/David-Gilmour-Tickets

Disclaimer: CapitalCityTickets.com is not associated with any artists, teams, venues, organizations, institutions, bands, or artists featured on their website in any way. Also, any names or titles used in this press release are solely for descriptive purposes and do not imply, indicate, or suggest any type of affiliation, partnership, or endorsement.

CapitalCityTickets.com is a reliable online marketplace serving the secondary market with tickets for all major concerts, sports, and theatre events. Online shoppers can take advantage of Promo Code “CITY5” while tickets last.

Check out the discount codes online for all upcoming events. CapitalCityTickets.com keeps low overheads which allow this trusted ticket site to keep prices competitive.

CapitalCityTickets.com | Live Customer Support | Order By Phone Toll Free | 7:00am-1:00am EST | (855) 514-5624

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/03/1458823436.jpeg

“David Gilmour Tickets for His Shows at the United Center and Auditoreum Theatre in Chicago are On Sale at CapitalCityTickets.com with Promo Code”

Media Contact
Company Name: CapitalCityTickets.com
Contact Person: Media Relations
Email: customerservice@capitalcitytickets.com
Phone: 1-855-514-5624
Country: United States
Website: http://www.capitalcitytickets.com/David-Gilmour-Tickets

Source: ABNewswire

ReleaseID: 57547

March 29, 2016 – – TheProductLawyers.com reports on another potential side effect warning from the U.S. Food and Drug Administration (FDA) which involves two similar drugs: Invokana and Invokamet. The drugs are both SGLT2 class inhibitors used to treat type-2 diabetes patients, and the FDA has recently indicated that they have received many adverse event reports surrounding the drugs linking them to weakened bone density and bone fracture risks among patients taking them.

The FDA stated, “Fractures were observed as early as 12 weeks after treatment initiation, and were more likely to be low trauma (e.g., arising after falls from no more than standing height) and affect the upper extremities.” They also reviewed a study which oversaw 714 elderly patients. Among these patients, results showed that those who were using Invokana had developed increased bone loss in their spine and hip areas. Warnings discussing side effects involving patient’s bones have been on the drug’s warning label since its release to market.

Invokana was released to market following its approval by the FDA in 2013. The drug was the first of a group of similar SGLT2 class inhibitor drugs to be released and, out of the group, reportedly currently has the most adverse events linked to it. The drug works by helping to maintain blood sugar (glucose) levels in type-2 diabetes patients. To accomplish this task, it prevents the kidneys from reabsorbing extra glucose, and instead rids the body of this glucose (sugar) through urination. To do this, however, Invokana must heavily rely on the kidneys and can allegedly stress or damage them as well.

The Endocrinologic and Metabolic Drugs Advisory Committee has also discussed bone density and bone fracture warnings surrounding these SGLT2 class inhibitor drugs. The committee noted bone density loss which was seen during clinical trials on the drugs. Reportedly, some patients taking the drugs have claimed to have broken bones after suffering just minor falls–such as tripping over something while on a walk.

The attorneys of Banville Law are dedicated to keeping all important drug information available to the general public. To better accomplish this, they sponsor the resource website TheProductLawyers.com, and are also working to assist patients who have taken SGLT2 class inhibitor drugs and who believe that their use of the drugs has caused them to suffer from adverse events. The attorneys of Banville Law believe that it is incredibly important to ensure that these patients will be given an opportunity to fully investigate their legal rights in the matter. To assist those desiring to explore these rights, they are currently offering free legal consultations for qualified parties. Affected patients may be entitled to substantial compensation.

To request additional Invokana lawsuit information, or to ask questions, contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008949

March 29, 2016 – – BloodThinnerHelp.com reports on the warnings issued by the FDA for the blood-thinning drug Xarelto since its approval in 2011. According to the FDA, Xarelto, manufactured by Johnson & Johnson and Bayer AG, has undergone several required warnings and changes to labeling and advertisements for the drug since it was approved.

From January to March 2014 the manufacturers were required by the FDA to make changes to the language on the “black box warning” on the drug. The addition was allegedly needed to warn users about dangerous side effects including a lack of antidote and the risks associated with using the drug with epidural anesthesia and spinal puncture.

The companies had to make changes to their advertisements after the FDA claimed that the companies downplayed the possible side effects associated with the drug. From May to November of 2012 the FDA Cardiovascular and Renal Drugs Advisory committee convened to discuss the possibility of extending Xarelto’s uses, according to the FDA. Though the committee decided not to approve the drug because of concerns about bleeding, the FDA expanded the use indicating in a press release that three studies indicated that the drug was safe for treatment of deep vein thrombosis and pulmonary embolism. The announcement also noted bleeding as a possible “major side effect.”

The companies also received post market requirements from the FDA including providing a low-dose tablet, conducting a clinical study to determine risks affiliated with renal impairment and to track “risk factors, clinical management and outcomes of all major bleeding events and to report them through a quarterly report for three years.”

Since the drug hit the market in 2011, thousands of lawsuits have been filed federally against the manufacturers by plaintiffs claiming the drug caused adverse side effects such as gastrointestinal bleeding, rectal bleeding, internal bleeding, stroke, heart attack, pulmonary embolism, epidural hematoma and brain hemorrhages. Those cases have been consolidated into a multidistrict litigation panel in Eastern Louisiana that has now reached 2,800 cases. Those filed in state court in Pennsylvania have been combined into a mass tort program that has reached 620 cases. Bellwether trials on federally-filed cases are scheduled to begin in February 2017.

Until those cases are brought to court, Attorney Joseph Osborne is working to ensure that those individuals who have used the drug and have been negatively affected are able to explore their legal rights. Qualifying individuals may be entitled to financial compensation and legal action. Osborne is currently offering free legal consultations for affected parties.

For more information about Xarelto, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008938

Patrick Magee releases SmartMenu, a Windows program that serves as an information repository hub

Image: http://pressreleasejet.com/uploads/newsreleases/author-software-architect-launches-solution-to-information-overload.png

BELLEVUE, WA – 29 Mar, 2016 – Patrick Magee, founder of BrainDance.com Inc and author of “Brain Dancing,” has released a new Windows application, SmartMenu, that serves as a portal for accessing a user’s frequently used information repositories.

he SmartMenu information portal, which retails for $9.95, can be customized to streamline access to a variety of search engines. SmartMenu’s can be created that launch searches against multiple related websites simultaneously, or that quickly look up data in line of business enterprise applications. An enterprise version of the software, which costs $48 per year, allows IT departments to create and deploy sets of “Smart” menu items based on an employee’s role or team.

Users are able to combine four different kinds of searches, browser-based, command line, SQL database and dynamically populated data-driven menu items.

“Being able to jump to a specific item on frequently used line of business sites, such as an order number or bug id, directly from SmartMenu is so much faster,” Magee said. “Early users loved the product even when they had to right-click on a system tray icon. Now all they have to do is press the Ctrl+Windows key combination.”

The UI is based on the more than five years of research that went into writing Magee’s book, “Brain Dancing”, available in Kindle format on Amazon.com for free 3/30-4/2/2016. “Brain Dancing” examines metacognition, or learning about how people learn, think and innovate, and gives readers a glimpse at the mental software that runs their brains. Metacognitive strategies are enhanced by optimizing mental clarity and by aligning metalearning processes with fundamental principles governing brain/mind interactions.

In addition to searching, SmartMenu allows users to task switch faster by creating groups of items that can be opened all at once. Traditional Windows start menu’s are organized around programs and files. SmartMenu increases user productivity by providing the ability to align information access based on project, task or work mode.

“I use SmartMenu’s project feature to streamline my daily workload. One click and all my spreadsheets, documents, websites and folders pertaining to a project open, saving me time and effort. It’s amazing!” – Willie McClure, CEO, Datarim, Inc

Magee is a 14-year veteran of Microsoft, is named as co-inventor on three Microsoft patents and his 200+ consulting clients range from Boeing to US Bank and Westin Hotels.

More information is available at http://BrainDance.com, by emailing info@BrainDance.com, or by calling (206) 659-7103.

BrainDance.com® is a registered trademark of BrainDance.com Inc.

A YouTube video introduction is available at https://youtu.be/_w7e-R-Cx6c

Video Link: https://youtu.be/_w7e-R-Cx6c

Full News Story: http://pressreleasejet.com/news/author-software-architect-launches-solution-to-information-overload.html

Media Contact
Company Name: BrainDance.com Inc
Contact Person: Patrick T Magee
Email: patm@braindance.com
Phone: (206) 659-7103
Country: United States
Website: http://BrainDance.com

ReleaseID: 541842

Source: GetNews